Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments. (TEAAMS)

Promotion of Exercise Behavior Among Rural-Residing African-Americans With Multiple Sclerosis

The proposed project involves a high-quality randomized controlled (RCT) design that examines the effects of a remotely-delivered, racially-tailored exercise training program for immediate and sustained improvement in walking dysfunction, symptoms, and health-related quality of life (HRQOL) among African-Americans with MS residing in rural environments. The primary analysis will test the hypothesis that those who are randomly assigned into the intervention condition (i.e., exercise training) will demonstrate (a) improvements in outcomes from baseline that (b) are sustained over 4-months of follow-up compared with those in the control condition (i.e., stretching).

Study Overview

• Status: Recruiting
• Conditions: Multiple Sclerosis
• Intervention / Treatment: Behavioral: Guidelines for Exercise in Multiple Sclerosis (GEMS); Behavioral: FLEX Stretching and Toning Program

Detailed Description

There is a lack of evidence from high-quality randomized controlled trials (RCTs) of exercise training for African-Americans with multiple sclerosis (MS), as only 1.7% of participants in physical activity and exercise research involving persons with MS identify as African-American. The population of African-Americans with MS deserves equal and focal research that addresses the unique challenges of MS in the African-American rural residing community. We uniquely address this population with a highly-developed and refined exercise training program that is racially-tailored for the target population. We further provide a highly-developed and refined exercise training program that can be undertaken in one's home and/or local community, and does not require facility access that is extremely limited in the target, rural residing population of persons with MS. The program is further tailored based on qualitative research and addresses the unique needs of the African-American community with MS. There is no other research program this advanced in study refinement and design for immediate integration into a high-quality RCT for changing the lives of African-Americans with MS who reside in rural communities of the Southeastern portion of the United States. If successful, the study, as designed, will provide Class I evidence that is necessary for immediate implementation after trial completion through insurance providers and healthcare providers, including physical therapists, rehabilitation practitioners, and community health workers/providers. This program further aligns with recently developed and highly-refined conceptual and practice models for implementation of exercise into the care of persons with MS.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Robert W Motl, PhD; Phone Number: 205-975-1306; Email: robmotl@uic.edu
• Study Contact Backup: Name: Edson Flores, MPH; Phone Number: 312-413-4967; Email: eflore42@uic.edu

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Recruiting
      • University of Illinois at Chicago
      • Contact: Robert W Motl, PhD; Phone Number: 205-975-1306; Email: robmotl@uic.edu
      • Contact: Edson Flores, MPH; Phone Number: 312-413-4967; Email: eflore42@uic.edu
      • Principal Investigator: Robert W Motl, PhD
      • Sub-Investigator: Edson Flores, MPH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• English as primary language
• Identify as African-American or Black
• Age of 18 years or older
• Diagnosis of MS
• Relapse free in the past 30 days
• Internet and email access
• Willingness to complete the outcome questionnaires
• Willingness to undergo randomization
• Insufficient physical activity (not meeting current physical activity guidelines based on GLTEQ)
• Mild-moderate ambulatory disability (MSWS-12 score between 25-49 & PDDS score between 2-4)

Exclusion Criteria:

• Individuals not meeting above inclusion criteria
• Individuals with moderate to high risk for contraindications of possible injury or death when undertaking strenuous or maximal exercise (PARQ).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Guidelines for Exercise in Multiple Sclerosis (GEMS); Participants in this condition will receive a 4-month home-based, remotely supported aerobic and resistance exercise program based on the Guidelines for Exercise in Multiple Sclerosis (GEMS).	Behavioral: Guidelines for Exercise in Multiple Sclerosis (GEMS); Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.
Sham Comparator: FLEX Stretching and Toning Program; Participants in this condition will receive a 4-month home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.	Behavioral: FLEX Stretching and Toning Program; Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Walking Dysfunction	Multiple Sclerosis Walking Scale-12 (MSWS-12); scores range between 0 (min) and 100 (max), higher scores reflect greater walking problems.	Changes in walking scores from Baseline, 4-months, and 8-months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disability	Patient Determined Disease Steps (PDDS) scale; scores range between 0 (min) and 8 (max), higher score reflect greater perceived disability.	Changes in disability scores from Baseline, 4-months, and 8 months.
Fatigue Severity	Fatigue Severity Scale (FSS); scores range between 1 (min) and 7 (max), higher scores reflect greater fatigue severity.	Changes in fatigue from Baseline, after 4-month intervention period, and 4 months after intervention cessation.
Depressive Symptoms	Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms.	Changes in depressive symptoms from Baseline, after 4-month intervention period, and 4 months after intervention cessation.
Anxiety	Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms.	Changes in anxiety symptoms from Baseline, after 4-month intervention period, and 4 months after intervention cessation.
Health-related Quality of Life (HRQOL)	Multiple Sclerosis Impact Scale (MSIS-29); scores range between 0 (min) and 100 (max), higher scores indicate greater impact of disease on daily function (i.e. worse outcomes).	Changes in quality of life from Baseline, after 4-month intervention period, and 4 months after intervention cessation.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exercise Behavior	Godin Leisure Time Exercise Questionnaire (GLTEQ); scores range between 0 (min) and 119 (max), higher scores indicate greater engagement in exercise behavior.	Changes in exercise behavior from Baseline, after 4-month intervention period, and 4 months after intervention cessation.

Collaborators and Investigators

• Sponsor: University of Illinois at Chicago
• Collaborators: Bristol-Myers Squibb; University of Alabama at Birmingham
• Investigators: Principal Investigator: Robert W Motl, PhD, University of Illinois at Chicago

Study record dates

Study Major Dates

• Study Start (Actual): September 2, 2022
• Primary Completion (Estimated): August 1, 2024
• Study Completion (Estimated): August 1, 2025

Study Registration Dates

• First Submitted: August 23, 2022
• First Submitted That Met QC Criteria: August 23, 2022
• First Posted (Actual): August 25, 2022

Study Record Updates

• Last Update Posted (Estimated): January 11, 2024
• Last Update Submitted That Met QC Criteria: January 10, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: African-American; Rural; Health-Related Quality of Life; Walking dysfunction
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Multiple Sclerosis; Sclerosis
• Other Study ID Numbers: 2022-0526; 20016 (Other Grant/Funding Number: Bristol Myers Squibb Foundation)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No